CO6680611A2 - The new stable polyethylene glycol conjugate of iinterferon alfa, represented by a positional isomer - Google Patents

The new stable polyethylene glycol conjugate of iinterferon alfa, represented by a positional isomer

Info

Publication number
CO6680611A2
CO6680611A2 CO13009157A CO13009157A CO6680611A2 CO 6680611 A2 CO6680611 A2 CO 6680611A2 CO 13009157 A CO13009157 A CO 13009157A CO 13009157 A CO13009157 A CO 13009157A CO 6680611 A2 CO6680611 A2 CO 6680611A2
Authority
CO
Colombia
Prior art keywords
conjugate
formula
ifn
peg
polyethylene glycol
Prior art date
Application number
CO13009157A
Other languages
Spanish (es)
Inventor
Tatyana Veniaminovna Chernovaskaya
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Angelina Vsevolodovna Klenova
Dmitriy Valentinovich Morozov
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6680611(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of CO6680611A2 publication Critical patent/CO6680611A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención está relacionada a la industria farmacéutica y medicina,, en particular, al nuevo PEG-interferón derivados y al descubrimiento de un conjugado nuevo funcional, altamente estable de interferón a polietileno glicol con una actividad de interferón alfa, con inmunogenicidad reducida, con efectos biológicos prolongados y parámetros fármaco-kinéticos mejorados de fórmula general.Donde:n- valores integrales de 227 a 10 000, así que el peso molecular de PEG es de alrededor de 10 000 - 40 000 Da;m - integer = 4;IFN - natural o recombinante polipéptido teniendo la actividad de IFN aIfa.También, la invención está relacionada a drogas conteniendo el declarado conjugado de la fórmula (I), composiciones farmacéuticas conteniendo PEG-IFN conjugado y terapéuticamente aceptable excipientes ideales para el tratamiento de infecciones virales y cáncer, también enfermedades asociadas con inmunodeficiencia primaria o secundaria. La invención está relacionada al uso de conjugado de fórmula (1) en productos medicinales, los cuales tienen actividad antiviral, antiproliferativa e inmunomodulatoria, aproximaciones y/o tratamiento de enfermedades asociadas con inmunodeficiencia primaria o secundaria de conjugado de fórmula (I) y al contenedor con tal composición farmacéutica.The invention relates to the pharmaceutical and medical industry, in particular, to the new PEG-interferon derivatives and to the discovery of a new, highly stable, functional conjugate of interferon to polyethylene glycol with an interferon alpha activity, with reduced immunogenicity, with effects prolonged biological and improved pharmaco-kinetic parameters of the general formula, where: n- integral values of 227 to 10,000, so the molecular weight of PEG is around 10,000 - 40,000 Da; m - integer = 4; IFN - Natural or recombinant polypeptide having the activity of IFN aIfa. Also, the invention is related to drugs containing the declared conjugate of the formula (I), pharmaceutical compositions containing conjugated PEG-IFN and therapeutically acceptable excipients ideal for the treatment of viral infections and cancer , also diseases associated with primary or secondary immunodeficiency. The invention relates to the use of conjugate of formula (1) in medicinal products, which have antiviral, antiproliferative and immunomodulatory activity, approaches and / or treatment of diseases associated with primary or secondary immunodeficiency of conjugate of formula (I) and the container With such pharmaceutical composition.

CO13009157A 2010-07-20 2013-01-18 The new stable polyethylene glycol conjugate of iinterferon alfa, represented by a positional isomer CO6680611A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (en) 2010-07-20 2010-07-20 NOVEL FUNCTIONALLY ACTIVE, HIGHLY PURE, STABLE CONJUGATE OF INTERFERON α WITH POLYETHYLENE GLYCOL, REPRESENTED BY ONE PEG- NαH-IFN POSITIONAL ISOMER, WITH IMPROVED IMMUNOGENICITY, WITH PROLONGED BIOLOGICAL ACTION, SUITABLE FOR MEDICAL APPLICATION, AND IMMUNOLOGICAL AGENT BASED THEREON

Publications (1)

Publication Number Publication Date
CO6680611A2 true CO6680611A2 (en) 2013-05-31

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13009157A CO6680611A2 (en) 2010-07-20 2013-01-18 The new stable polyethylene glycol conjugate of iinterferon alfa, represented by a positional isomer

Country Status (20)

Country Link
KR (1) KR101586372B1 (en)
CN (1) CN102617736B (en)
AR (1) AR087227A1 (en)
BR (1) BRPI1101565A2 (en)
CO (1) CO6680611A2 (en)
CR (1) CR20130021A (en)
CU (1) CU24193B1 (en)
DO (1) DOP2013000002A (en)
EA (1) EA020257B1 (en)
EC (1) ECSP13012398A (en)
HK (1) HK1170504A1 (en)
MX (1) MX2011007458A (en)
MY (1) MY168784A (en)
NI (1) NI201300008A (en)
PE (1) PE20131034A1 (en)
RU (1) RU2447083C1 (en)
SG (1) SG187117A1 (en)
UA (1) UA99766C2 (en)
UY (1) UY33525A (en)
WO (1) WO2012011836A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (en) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") HYBRID PROTEIN HAVING PROLONGED ACTION, BASED ON RECOMBINANT HUMAN INTERFERON ALPHA-2 (VARIANTS), METHOD OF ITS PRODUCTION AND STRAIN OF Saccharomyces cerevisiae FOR IMPLEMENTING THIS METHOD (VERSIONS)
EA021643B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Monopegylated interferon-alpha of linear structure and a pharmaceutical composition for preparing a medicament having interferon-alpha activity
EA021610B1 (en) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Liquid antiviral formulation
CN103463623B (en) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 A kind of Peg-IFN alpha-2b injection and preparation method thereof
RU2554761C1 (en) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Anti-enteroviral and immunostimulating agent
RU2572800C1 (en) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" New formulation containing polyethylene glycol (peg) conjugated interferon alpha-2beta characterised by less painful administration
EA029498B1 (en) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ANTI-TUMOUR DRUG BASED ON RECOMBINANT INTERFERON ALPHA-2b IN THE FORM OF MICROPARTICLES FOR PARENTERAL ADMINISTRATION
RU2678332C1 (en) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Pegylated interferon lambda with high bioaccessability in oral use and method for production thereof
AU2021258734A1 (en) * 2020-04-20 2023-01-05 Altum Pharmaceuticals Inc. Recombinant interferon
CN114392237B (en) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 Freeze-dried virus preparation and preparation method thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
JP2758154B2 (en) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー Liquid preparations containing interferon
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
RS20050202A (en) * 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
RU2311930C2 (en) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Pagylated interferon against viral infection
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
US7872082B2 (en) * 2005-07-19 2011-01-18 Nektar Therapeutics Method for preparing polymer maleimides
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease
CN101491682A (en) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 PEG-IFN omega conjugate and preparation technique thereof
CN101591387A (en) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 PEG-IFN omega conjugate
CN101514229B (en) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 Human interferon alpha derivative and polyethylene glycol modified substance thereof

Also Published As

Publication number Publication date
CU20130013A7 (en) 2013-04-19
EA020257B1 (en) 2014-09-30
KR101586372B1 (en) 2016-01-18
HK1170504A1 (en) 2013-03-01
MX2011007458A (en) 2012-01-19
KR20130056885A (en) 2013-05-30
BRPI1101565A2 (en) 2012-12-04
ECSP13012398A (en) 2013-05-31
SG187117A1 (en) 2013-02-28
CN102617736B (en) 2015-11-25
CN102617736A (en) 2012-08-01
CR20130021A (en) 2013-02-20
WO2012011836A1 (en) 2012-01-26
RU2010129824A (en) 2012-01-27
DOP2013000002A (en) 2013-09-15
PE20131034A1 (en) 2013-09-27
AR087227A1 (en) 2014-03-12
NI201300008A (en) 2014-05-26
UY33525A (en) 2012-02-29
CU24193B1 (en) 2016-09-30
MY168784A (en) 2018-12-04
RU2447083C1 (en) 2012-04-10
UA99766C2 (en) 2012-09-25
EA201100809A1 (en) 2012-01-30

Similar Documents

Publication Publication Date Title
CO6680611A2 (en) The new stable polyethylene glycol conjugate of iinterferon alfa, represented by a positional isomer
DOP2011000343A (en) PIRIDINE TIENO DERIVATIVES [2,3-B] AS VIRAL REPLICATION INHIBITORS
US10544193B2 (en) Compositions and methods for treating diseases by inhibiting exosome release
HUP0302319A2 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
AR067184A1 (en) USE OF 6- (3-CHLORO-2-FLUORBENCIL) -1 - [(2S) -1-HIDROXI-3-METILBUTAN-2-IL] -7-METOXI-4-OXO-1,4-DIHYDROCHINOLINE-3- CARBOXILICO. PHARMACEUTICAL COMPOSITION
MD4430C1 (en) Compositions and methods for treating hepatitis C virus
CO6501124A2 (en) IMMUNOMODULATING POLYPEPTIDES DERIVED IS THE IL 2 AND ITS THERAPEUTIC USE IN CANCER AND IN CHRONIC INFECTIONS
DOP2014000271A (en) NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL
ECSP13012399A (en) A NEW COLONIA-STIMULATING FACTOR GRANULOCIT CONJUGATE (G-CSF) WITH POLYETHYLENE
FI3511004T3 (en) Combined preparations for the treatment of cancer
RU2013148779A (en) TREATMENT OF HEPATITIS VIRUS INFECTION IN SEPARATELY OR IN COMBINATION WITH DELTA HEPATITIS VIRUS AND LIVER-LIVING DISEASES OF THE LIVER
BR112022010574A2 (en) PHARMACEUTICAL COMPOSITIONS INCLUDING CABOTEGRAVIR
AR114323A1 (en) MODIFIED RELAXIN B-CHAIN PEPTIDES AND THEIR THERAPEUTIC USE
AR093476A1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ECTODERMAL DYSPLASIA
JP2013542196A5 (en)
KR20070012522A (en) Treatment or prevention of respiratory viral infections with immunomodulator compounds
DOP2022000004A (en) PHARMACEUTICAL COMPOSITIONS RESISTANT TO THE DISCHARGE OF DOSES THAT INCLUDE VENIRUNAD
TH133837A (en)
BR112015010650A2 (en) improved levonorgestrel-containing composition only for optimized oral contraception with defined levonorgestrel content, dosage regimen and pharmaceutical preparation
Bolhassani Target molecules and delivery vehicles for anti-HIV drugs in vitro and in vivo
EP4269424A1 (en) Novel antiviral compounds and use thereof
RU2014116988A (en) ALISPORIVIR FOR TREATING INFECTIONS CAUSED BY HEPATITIS C VIRUS
EA202090135A1 (en) NEW COMPOSITIONS OF 2- (IMIDAZOL-4-YL) ETHANAMIDE PENTANDIOVIC-1,5 ACID FOR TREATMENT AND PREVENTION OF VIRAL DISEASES
EP4329792A1 (en) Compound for treating covid-19 infections
EA202091320A1 (en) LOCAL APPLICATION OF DIOXIDINE FOR INFECTIOUS INFLAMMATORY LESIONS OF THE EPITHELIUM